This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: L10.0 (Pemphigus vulgaris) | Special Copayment Reduction: V132 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood: very high — pemphigus vulgaris is mostly first diagnosed in adults in their 40s–60s, and pediatric onset is rare. Oral mucosal erosions often precede and develop into skin blisters months later, so adult onset is the typical clinical pattern. |
| 1. History | 18th century: descriptions begin in Europe → 1964: Beutner and Jordon discover IgG autoantibodies → 1979: desmoglein antigen identified → treatment revolutionized by the introduction of rituximab. |
| 2. Causes | Loss of adhesion between keratinocytes due to IgG4 autoantibodies against the desmoglein 3 (and 1) protein. Combined action of genetic predisposition (HLA-DRB1*04:02, DQB1*05:03) and environmental factors. |
| 3. Genetics | Strong association with HLA class II genes. Variants in the DSG3 gene itself are not the cause. Specific HLA haplotypes are frequent in Jewish and Mediterranean populations. |
| 4. General epidemiology | Annual incidence of 1–5 per million population. Also occurs rarely in East Asia, including Korea. Most common in people in their 40s–60s. Similar in men and women, or slight female predominance. |
| 5. Pathophysiology | Anti-DSG3 IgG4 antibodies bind to desmoglein 3 of the desmosome → separation of keratinocytes (acantholysis) → formation of suprabasal intraepidermal blisters. |
| 6. Symptoms | Oral mucosal erosions and pain (preceding), flaccid skin blisters, positive Nikolsky sign, dysphagia, weight loss. |
| 7. Signs | Flaccid blisters, Nikolsky sign, Asboe-Hansen sign, extensive erosions and crusts, signs of secondary infection. |
| 8. Screening | Anti-DSG3 and anti-DSG1 ELISA, indirect immunofluorescence (IIF). Direct immunofluorescence (DIF) of a biopsy of suspicious lesions. |
| 9. Diagnosis | Biopsy histopathology (suprabasal acantholysis), DIF (intercellular net-like IgG and C3 deposition between keratinocytes), quantification of autoantibodies by ELISA. |
| 10. Treatment | Systemic corticosteroids (first line), rituximab (CD20-targeted B-cell depletion), azathioprine and mycophenolate mofetil (steroid-sparing), IVIG. |
| 11. Prognosis | Complete remission rate improved after the introduction of rituximab. Long-term steroid adverse effects are the main cause of morbidity. Mortality has decreased, but caution is needed for complications such as sepsis. |
| 12. Prevention | Maintenance treatment to prevent relapse, infection prevention (vaccination, skin wound care), strategies to minimize steroid adverse effects. |
| 13. References | Murrell DF et al. J Am Acad Dermatol 2020 and 9 others. |
The history of Pemphigus Vulgaris dates back to 18th-century European medical literature. The term 'Pemphigus' derives from the Greek 'pemphix (blister)', and the name became established when the British physician Robert Willan systematically classified blistering skin diseases in 1791. In the 19th century, blistering diseases in general were collectively called pemphigus, but without an understanding of the pathophysiology, treatment was nearly impossible and mortality was extremely high. Until the early 20th century, pemphigus vulgaris was regarded as a fatal disease leading to death within a few years of diagnosis.
The first turning point in the history of treatment was the introduction of systemic corticosteroids in the 1950s. Before the use of corticosteroids, the 5-year mortality of pemphigus vulgaris was over 75%, but it decreased sharply after the introduction of steroid therapy. However, adverse effects of long-term high-dose steroid use, such as infection, osteoporosis, and diabetes, emerged as a new problem.
The breakthrough in immunological understanding began in 1964, when Ernst Beutner and Robert Jordon discovered IgG autoantibodies binding to the keratinocyte surface in the sera of patients with pemphigus vulgaris. This research first proved that pemphigus vulgaris is an autoimmune blistering disease. In 1979, the target antigen of the autoantibodies was identified as desmoglein (DSG), a desmosomal protein, and the molecular structure of the antigen was subsequently elucidated in the 1980s–90s. In the 1990s, combination with immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil) made steroid tapering possible.
The most important treatment innovation of the 21st century is the introduction of rituximab, a CD20-targeted antibody. In 2017, the French RITUX3 randomized controlled trial proved that rituximab markedly improves the complete remission rate compared with conventional immunosuppressants, after which it was approved for moderate-to-severe pemphigus vulgaris by the European Medicines Agency (EMA) and the US FDA. Recently, new targeted therapies such as FcRn inhibitors (efgartigimod alfa), Bruton's tyrosine kinase (BTK) inhibitors, and IL-4/13 blockers are in clinical trials. In Korea, rituximab became covered by National Health Insurance for the treatment of pemphigus in 2019, greatly improving access to treatment.
Pemphigus vulgaris is an autoimmune blistering disease caused by IgG autoantibodies against the desmoglein 3 (DSG3) protein, which makes up the desmosome, the adhesion structure between keratinocytes of the skin and mucosa. Anti-DSG3 IgG antibodies are detected in the majority of patients with pemphigus vulgaris, and when skin involvement is present, anti-DSG1 antibodies are also often positive. DSG3 is expressed mainly in the basal and suprabasal layers of the epidermis and is evenly distributed throughout the full thickness of the oral mucosa, so DSG3 autoantibodies preferentially involve the oral mucosa.
The autoantibody subclass is mainly IgG4, with partial involvement of IgG1. The main proposed mechanism is that IgG4 antibodies bind to the extracellular domains (EC1-EC2) of DSG3 and directly sterically block the heterophilic interactions of desmoglein (DSG3-DSG3, DSG3-DSG1 trans-binding). In addition, it has been confirmed experimentally that activation of signaling (p38 MAPK, Src kinase pathways) and desmosome dissociation via intracellular signaling are involved.
Genetic predisposition plays an important role in the development of pemphigus vulgaris. The most strongly associated genetic factors are HLA class II genes; in particular, the HLA-DRB1*04:02 and HLA-DQB1*05:03 alleles are reported at high frequency in Ashkenazi Jewish and Mediterranean patients. Associations with HLA-DR4 and DR14 have also been reported in Asian and South American patient populations. Besides HLA genes, non-HLA genes (common autoimmunity genes such as PTPN22, CTLA4, and TNFAIP3) have also been reported as risk factors. Reported environmental triggers include drugs (penicillamine, ACE inhibitors, thiol-containing drugs), thermal injury, UV light, certain foods (green onion, garlic, thiol-containing foods), and infections (some viruses), but establishing causality in individual patients is difficult.
Pemphigus vulgaris occurs sporadically, and familial clustering is rare. However, relatively high incidence has been reported in Jewish and Mediterranean populations with homozygous HLA genotypes. Molecular mimicry — a mechanism in which an immune response to viral or bacterial antigens structurally similar to DSG3 leads to cross-reaction — has been proposed as a hypothesis for the trigger initiating the autoimmune mechanism. In addition, evidence is accumulating that regulatory T cell (Treg) dysfunction and DSG3 epitope-specific activation of CD4+ helper T cells promote B-cell differentiation and the production of high-affinity autoantibodies.
Pemphigus vulgaris is a complex genetic disease that does not follow Mendelian inheritance and is not caused by a single-gene variant. The most firmly established genetic risk factors are the HLA (Human Leukocyte Antigen) class II genes; in particular, specific alleles of the HLA-DRB1 and HLA-DQB1 genes located on the short arm of chromosome 6 (6p21.3) are strongly associated with the development of this disease.
In the Ashkenazi Jewish population, the HLA-DRB1*04:02 allele has been reported to have a strong association, with an odds ratio (OR) of about 20–30. In Mediterranean populations, HLA-DRB1*14:01 and DQB1*05:03 are the main risk alleles. In East Asian patients, including Koreans, HLA-DRB1*14:01 and HLA-DRB1*04:06 have been reported to be associated. Because HLA class II molecules present antigenic peptides to CD4+ T cells, the association is explained by specific HLA genotypes presenting DSG3 peptides more efficiently and thereby promoting activation of autoreactive T cells.
Beyond HLA, non-HLA risk genes have also been identified in genome-wide association studies (GWAS). That specific single nucleotide polymorphisms (SNPs) of the ST18 (suppression of tumorigenicity 18) gene are associated with increased risk of pemphigus vulgaris was first reported in a 2012 Israeli GWAS, and ST18 is highly expressed in DSG3-expressing cells and may promote antigen presentation. Associations with several common autoimmune risk genes such as PTPN22 and TNFAIP3 have also been reported in some patient groups. No pathogenic variants directly associated with the development of pemphigus vulgaris have been identified in the DSG3 gene (18q12.1) itself.
The overall effect of genetic risk factors is necessary but not sufficient for disease development, and interaction with environmental triggers is essential for onset. The clinical implications of genetic counseling are limited, and the risk of recurrence within a family is only slightly higher than in the general population. Genetic testing is mainly used for research purposes rather than diagnostic confirmation.
Pemphigus vulgaris is a rare autoimmune blistering disease worldwide, and its annual incidence varies by region and ethnicity but is generally reported as 1–5 per million population. Relatively high incidence (10–30 per million population) is observed in Iran, Israel (Ashkenazi Jews), and parts of India, which is related to the high frequency of specific HLA risk genotypes. Low incidence (1–3 per million) is typical in Europe, North America, and East Asia.
Age of onset is mainly in the 40s–60s, but it also occurs in young adults in their 20s–30s and in the elderly. Pediatric pemphigus vulgaris is rare but has been reported. Sex distribution varies by study, but overall a slight female predominance (female:male = about 1.5:1) or a similar distribution is reported. In Korea, it is estimated that several hundred new diagnoses are made annually through the rare disease registration system, but accurate domestic statistics are limited. According to Health Insurance Review & Assessment Service (HIRA) data, the total number of patients treated for pemphigus-like diseases (L10 classification) is in the thousands.
The prevalence of pemphigus vulgaris is gradually increasing as improved treatment extends patient survival. A relatively high burden is observed in countries with many ethnic risk groups (Ashkenazi Jews, Iranians, Indians), and in immigrant populations the incidence pattern of the original population is largely maintained. The rate of comorbid autoimmune diseases (rheumatoid arthritis, autoimmune thyroid disease, myasthenia gravis, etc.) is higher than in the general population, and some association with malignancies (especially thymoma) has also been reported.
Associations with seasonal variation or specific environmental factors are unclear, but UV exposure, thermal injury, and taking certain drugs are regarded as triggers. In drug-induced pemphigus, thiol-containing drugs such as penicillamine and captopril are the best-known causes, and remission is often achieved after discontinuing the drug.
The core pathophysiology of pemphigus vulgaris is acantholysis — loss of adhesion between epidermal keratinocytes — which is mediated by IgG autoantibodies targeting desmoglein 3 (DSG3), a desmosomal protein. The desmosome is a specialized cell adhesion complex that mechanically links the cell membranes of adjacent keratinocytes and is composed of DSG3, DSG1, desmocollin, plakophilin, desmoplakin, and others.
The pathogenic mechanism of the autoantibodies is explained by two main mechanisms. First, the direct steric hindrance mechanism: anti-DSG3 IgG antibodies bind to the extracellular domain of DSG3 (especially EC1) and physically block trans-binding between DSG3 molecules of adjacent cells. As a result, desmosomal adhesion cannot be maintained and keratinocytes separate. Second, the signaling-mediated mechanism: autoantibody binding activates intracellular signaling pathways (p38 MAPK, Src kinase, PLC-γ, caspase), promoting phosphorylation, internalization, and degradation of desmosomal proteins. The two mechanisms act complementarily to cause acantholysis.
Histopathologically, a cleft forms just above the basal layer (suprabasal) within the epidermis, and this space expands to form a blister (bulla). The basal keratinocytes remain attached to the basement membrane, forming a 'tombstone pattern'. Within the blister are acantholytic keratinocytes (acantholytic cells, Tzanck cells) and a small number of inflammatory cells. In the oral mucosa, DSG3 is highly expressed throughout the full thickness of the epithelium, so oral mucosal involvement appears first and is more persistent.
DSG3-specific CD4+ T helper cells (Th) play a central role in initiating and maintaining the autoimmune response. When antigen-presenting cells (dendritic cells, Langerhans cells) present DSG3 protein fragments on HLA class II molecules, autoreactive CD4+ T cells are activated and differentiate into Tfh (follicular helper T) cells, inducing antibody production and class switching by B cells. Restoring the suppressive function of DSG3-specific Treg cells is important in inducing remission. The therapeutic mechanism of rituximab is that it depletes CD20+ B cells, suppressing autoantibody production while also reducing the antigen-presenting function of B cells.
The clinical symptoms of pemphigus vulgaris are characterized by flaccid blisters (bullae) and erosions on the skin and mucosa, and in most patients oral mucosal lesions precede skin lesions, appearing months to more than a year earlier. Initially, intraoral blisters form but soon rupture, leaving persistent painful erosions, and patients complain of oral pain, dysphagia, and weight loss. Oral lesions involve the buccal mucosa, gingiva, hard palate, soft palate, tongue, and oropharynx, and persistent erosions lead to poor oral hygiene and predispose to secondary infection.
Skin symptoms mainly begin in areas subject to pressure or frequent friction, such as the scalp, face, chest, back, axillae, and groin. Blisters range in size from a few millimeters to several centimeters and arise on skin that appears nearly normal or on erythema. The blister wall is very thin and fragile (flaccid) and ruptures easily, so few patients actually reach the clinic with intact blisters; most present with painful erosions and crusts (scabs). Eroded areas become covered with blood and exudate, and healing is very delayed.
The Nikolsky sign is a phenomenon in which applying light friction near apparently normal skin causes the epidermis to slide off, and it is positive in pemphigus vulgaris. This sign reflects weakened epidermal cohesion due to acantholysis and is a diagnostic clue.
Extraoral mucosal symptoms may include involvement of the pharynx and larynx (voice change, dyspnea), esophagus (esophageal stricture, dysphagia), nasal mucosa (epistaxis, crusting), conjunctiva (dry eye, redness), and erosions of the anal and genital mucosa. As for systemic symptoms, extensive skin lesions may be accompanied by fluid loss, electrolyte imbalance, hypoproteinemia, and secondary bacterial infection (Staphylococcus, Streptococcus, Candida), leading to situations requiring inpatient treatment. In severe pemphigus vulgaris, sepsis remains a main cause of death, so active wound care and infection surveillance are essential.
The physical signs of pemphigus vulgaris reflect the severity and activity of this immunobullous disease, and various findings appear in the acute and chronic phases. The most characteristic physical finding is the flaccid blister, which contains serous or hemorrhagic fluid and has a very thin wall that easily spreads or ruptures when pressed with a finger. Erosions remaining after rupture are well demarcated and moist, heal slowly, and often leave hyperpigmentation after spontaneous healing.
The Nikolsky sign is the most important finding on clinical examination, a phenomenon in which the epidermis separates easily when a finger is placed on apparently normal skin and lateral pressure is applied. The phenomenon in which a blister extends laterally when pressure is applied at its margin is called the Asboe-Hansen sign, and these two signs are used as clinical tools to simply assess the activity of pemphigus vulgaris. When both signs disappear in response to treatment, this is regarded as an indicator of clinical remission.
On examination of the oral mucosa, erosions and ulcers with irregular borders are observed on the buccal mucosa, gingiva, hard palate, and soft palate. The lesions are painful and cause severe discomfort when eating. Blister remnants (bulla remnants) may be observed around the erosions. Examination of other mucosal sites — conjunctiva, nasal cavity, pharynx, esophagus, anogenital region — may also reveal erosions and ulcers, which is important in assessing the extent of the disease.
On skin examination, lesions at various stages coexist: intact flaccid blisters, fresh erosions, healing erosions covered with scabs, and hyperpigmented scars. With scalp involvement, erosive scalp dermatitis and crusts may be observed, and hair loss (telogen effluvium) may occur. With extensive skin involvement, a considerable part of the body surface area is covered by erosions, increasing the risk of impaired thermoregulation, loss of the skin barrier, and secondary infection. The Pemphigus Disease Area Index (PDAI) or the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) is used to assess severity.
Laboratory findings may include positive anti-DSG3 ELISA (active phase), elevated high-sensitivity C-reactive protein (CRP), peripheral blood eosinophilia, hypoalbuminemia (with extensive exudation), leukocytosis with secondary infection, and positive blood cultures. During treatment, anti-DSG3 antibody titers generally correlate with clinical activity but do not always match.
Because pemphigus vulgaris is a rare autoimmune disease, universal screening of the general population is not recommended. However, rapid and systematic diagnostic screening is essential in suspected patients (recurrent, nonhealing oral erosions, flaccid blisters, positive Nikolsky sign, skin erosions). In particular, in oral medicine or oral pathology, it is standard practice to classify patients with unexplained oral erosions persisting for 2 weeks or more as suspected pemphigus vulgaris and perform immunological testing.
Serum autoantibody testing: the primary screening test for pemphigus vulgaris is ELISA (enzyme-linked immunosorbent assay) to quantify anti-DSG3 and anti-DSG1 antibodies. Anti-DSG3 ELISA has high diagnostic value, with sensitivity and specificity of about 95–98% each for the oral (mucosal dominant) type of pemphigus vulgaris. When skin involvement is present, anti-DSG1 antibodies are also often positive. Anti-DSG1 positivity alone suggests pemphigus foliaceus. ELISA values are generally proportional to disease activity and are also used to monitor treatment response and predict relapse.
Indirect immunofluorescence (IIF): using frozen sections of monkey esophagus or human skin as the substrate, fluorescence of IgG in a net-like (fishnet) pattern in the intercellular space between keratinocytes strongly suggests a pemphigus-group disease. Combining it with ELISA can increase diagnostic specificity. The autoantibody titer is quantified and used to track treatment effect and relapse.
When positive findings are confirmed on screening tests, confirmation by tissue biopsy is needed. In choosing the biopsy site, the specimen for direct immunofluorescence (DIF) is taken from the border of a fresh blister (perilesional normal skin), and the specimen for routine histopathology is taken from the blister or erosion itself. Performing both tests together is the standard for increasing diagnostic accuracy.
The diagnosis of pemphigus vulgaris is made by integrating four elements: clinical findings, histopathology, direct immunofluorescence (DIF), and serum autoantibody testing. The 2020 international pemphigus committee guidelines recommend that histopathology and DIF be performed as essential for diagnosis, with serum antibody testing complementing them.
Histopathological examination: tissue is obtained by a 4–6 mm punch biopsy from the border of a fresh blister or erosion. On hematoxylin-eosin (H&E) staining, a suprabasal intraepidermal cleft and blister formation, a tombstone pattern of basal keratinocytes, and acantholytic cells within the blister are observed. Infiltration of eosinophils, lymphocytes, and neutrophils may be present within the blister and in the adjacent dermis. Bullous pemphigoid (BP), a differential diagnosis, shows subepidermal blisters, so the two diseases can be distinguished.
Direct immunofluorescence (DIF): a specimen taken from normal skin or mucosa near the lesion is frozen-sectioned and stained with fluorescent anti-IgG, anti-IgA, anti-IgM, and anti-C3 antibodies. The typical finding of pemphigus vulgaris is net-like IgG (and C3) deposition in the intercellular space between keratinocytes. DIF has a very high diagnostic sensitivity of about 90–95% for pemphigus vulgaris, and tissue deposition may be positive even when serum antibody titers are still low, so it is regarded as the standard for diagnostic confirmation. However, false negatives are possible if the specimen is inadequate (formalin fixation not possible; immediate storage in Michel's solution needed) or during immunosuppressive treatment.
Serum ELISA: anti-DSG3 ELISA (sensitivity 95–98%, specificity 95% or more) and anti-DSG1 ELISA are performed. Antibody titers often correlate with disease activity, and in complete remission titers often decrease markedly or become negative. However, because antibody positivity may persist even after clinical remission, the decision to stop treatment should not be based on antibody titers alone. Anti-BP180 and anti-BP230 ELISA are also performed for differential diagnosis (bullous pemphigoid).
Additional tests: indirect immunofluorescence (IIF), immunoblot, and flow cytometry (anti-DSG3 T-cell analysis) are used complementarily in difficult cases. The international pemphigus diagnostic criteria (2020 unpublished results) describe that diagnosis is possible with a combination of clinical findings + DIF, or clinical findings + serum antibodies + histopathology.
Treatment of pemphigus vulgaris aims to suppress autoantibody production, control active lesions, and minimize steroid adverse effects. Treatment strategy is individualized according to disease severity (mild, moderate, severe). The description is based on the 2020 European Dermatology Forum (EDF) and International Pemphigus Committee (IPC) guidelines and the latest 2023 clinical recommendations.
Systemic corticosteroids (first-line treatment): start with prednisolone or methylprednisolone 0.5–1.5 mg/kg/day and taper gradually as clinical activity decreases. An initial dose of 0.5 mg/kg/day is recommended for mild cases and 1–1.5 mg/kg/day for severe cases. Long-term high-dose steroid monotherapy causes serious adverse effects such as osteoporosis, diabetes, infection, gastric ulcer, and adrenal suppression, so the goal is early tapering with concomitant immunosuppressants. When using steroids, bisphosphonates, calcium, vitamin D, gastric mucosal protectants, and monitoring for hyperglycemia are recommended together.
Rituximab (first-line or early combination): a chimeric monoclonal antibody targeting CD20-positive B cells, which in the 2017 RITUX3 trial significantly improved the complete remission rate compared with conventional immunosuppressive therapy (34% vs 0% at 24 months). The EDF/IPC 2020 guidelines strongly recommend early combination of corticosteroids and rituximab in patients with moderate to severe pemphigus vulgaris. Standard dose: 1,000 mg intravenously twice (2 weeks apart, rheumatoid arthritis regimen) or 375 mg/m² four times (lymphoma regimen). Thereafter, a maintenance approach of repeating 500 mg every 6 months is also used to prevent relapse. Major adverse effects: hypogammaglobulinemia due to B-cell depletion, opportunistic infections, hepatitis B reactivation (pre-treatment testing mandatory), infusion reactions.
Steroid-sparing immunosuppressants: azathioprine (1–3 mg/kg/day), mycophenolate mofetil (2–3 g/day), cyclophosphamide (severe refractory cases), etc. are used for steroid tapering and maintenance of remission. The azathioprine dose is determined after TPMT activity testing, and cytopenias, hepatotoxicity, and infection risk are monitored.
Intravenous immunoglobulin (IVIG): high-dose IVIG (2 g/kg, divided over 2–5 days) rapidly reduces antibody titers and is used as an adjunct during pregnancy, in patients at high risk of infection, and in patients with contraindications to steroids. Plasmapheresis is also considered for rapid antibody removal in acute severe flares, but its effect when used alone is short-lived, so combination with immunosuppressants is needed.
Topical treatment: antibacterial dressings (silver-containing dressings, silicone dressings), topical corticosteroid ointments, and topical antifungals (for secondary Candida infection) are used on active skin erosions. For oral lesions, chlorhexidine mouthwash, topical steroid gels, and mucosal protectants (sucralfate suspension) help relieve pain and prevent infection.
New therapies (clinical use expanding): the neonatal Fc receptor (FcRn) inhibitor efgartigimod alfa shortens the half-life of IgG antibodies and rapidly lowers autoantibody titers; phase 3 trials were completed in 2023–2024 and it received FDA approval for pemphigus vulgaris. BTK inhibitors (zanubrutinib, rilzabrutinib) are in clinical trials aiming to reduce autoantibodies by inhibiting B-cell signaling.
The prognosis of pemphigus vulgaris has improved greatly with advances in treatment. Before the introduction of corticosteroids, most patients died within a few years of diagnosis, but now complete remission or good disease control is possible in the majority of patients with appropriate treatment. Since the recent introduction of rituximab, the complete remission rate has improved further, and the proportion of patients maintaining long-term remission is increasing.
The long-term course of pemphigus vulgaris takes three main patterns: ① complete remission (no relapse after stopping treatment), ② sustained remission (remission under maintenance medication), ③ repeated relapse. In the RITUX3 trial, the rituximab plus steroid group had a complete remission rate of 34% at 24 months and a clinical remission rate, including partial remission, of over 90%. There are also reports that about 50–60% of patients reach complete remission on long-term follow-up.
In terms of mortality, current causes of death in pemphigus vulgaris are mainly complications of the disease itself (sepsis, extensive loss of the skin barrier) and treatment-related adverse effects (infection due to immunosuppression, long-term steroid adverse effects). Mortality is higher in untreated or inadequately treated patients, and the long-term survival of patients managed at specialized dermatology centers is approaching a level similar to that of the general population. Older age at onset, extensive skin involvement, high autoantibody titers, and accompanying secondary infection are reported as poor prognostic factors.
Rapid decrease in anti-DSG3 ELISA titers, complete B-cell depletion after rituximab administration, and rising anti-DSG3 titers at relapse are used as predictors of treatment response. Relapse often occurs after stopping treatment or when tapering immunosuppression, and remission can mostly be induced again by re-administration of rituximab. Close surveillance for the cumulative risk of hypogammaglobulinemia and infection risk associated with repeated rituximab administration is important in long-term management.
Pemphigus vulgaris arises through an autoimmune mechanism, and primary prevention (preventing the onset itself) is currently not possible. The focus of prevention is on preventing relapse and complications. Maintenance treatment, infection prevention, avoidance of triggers, and minimizing treatment adverse effects are the key elements of prevention.
Maintenance treatment to prevent relapse: even after clinical complete remission and seroconversion to antibody negativity, immunosuppressive treatment is not stopped abruptly but tapered gradually. Regular maintenance administration of rituximab (e.g., 500 mg every 6–12 months) is effective in lowering the relapse rate. Steroids are tapered to the lowest possible maintenance dose or discontinued, but abrupt discontinuation must always be avoided.
Infection prevention: patients receiving immunosuppressive treatment should receive pneumococcal, influenza, hepatitis B, and herpes zoster vaccinations. Live vaccines (measles, varicella, yellow fever, etc.) are contraindicated during immunosuppression. Maintaining oral hygiene, early care of skin wounds, and avoiding artificial nails and skin trauma are important for preventing secondary infection. Testing for tuberculosis (TST or IGRA) and hepatitis B and C viruses is mandatory before rituximab administration, and preventive anti-tuberculosis treatment is given if latent tuberculosis is positive.
Avoiding triggers: when pemphigus vulgaris develops in patients taking penicillamine, ACE inhibitors, or other thiol-containing drugs, discontinuing the drug is the priority. Where known, avoid excessive UV exposure, thermal injury, and severe skin friction.
Preventing steroid adverse effects: patients on long-term steroids need bisphosphonates (osteoporosis), calcium and vitamin D supplementation, blood glucose monitoring, gastric mucosal protectants, and regular checks of intraocular pressure and for cataracts. Patient education emphasizes preventing unauthorized discontinuation of steroids, taking medication regularly, and early recognition and reporting of adverse effects. Regular follow-up with a dermatologist is essential for early detection of relapse and early treatment intervention.